PO BOX 508
Malvern, PA 19355
You can pay online by logging onto https://cardionet.mybalanceonline.com/
Create a One-Time Payment or Secure Online Account.
Call to make payment: 877-837-6027 M-Th 8AM-6PM, Fri 8AM-5PM, Sat 9AM-2PM Eastern Standard Time.
You can follow the patient payment link below where you can pay with the Papaya App.
For technical support please call 1-619-376-1925.
You can pay online by logging onto https://ppaya.com/pay/payment.php?p=mAD9as9nyM/
April 25, 2019
Achieves Record Quarterly Revenue
Raises Full Year 2019 Guidance
MALVERN, Pa., April 25, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the first quarter ended March 31, 2019.
President and CEO Commentary
Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “The first quarter was another great quarter with record revenue and a strong adjusted EBITDA margin, both of which were in line with our expectations. Demand for our services remained strong with MCT and extended Holter services driving patient volume growth as well as a 9% increase in Healthcare revenue. Additionally, our Research division posted double-digit revenue growth while our digital population health business benefitted from the launch of a significant new managed care partnership.
“During the quarter, we completed the acquisition of Geneva Healthcare, extending our remote cardiac monitoring reach into the $1 billion implantable cardiac monitoring market. We believe this transaction further reinforces our growth strategy and provides significant revenue upside for the company. Our excitement about Geneva continues to grow based on its early performance and the tremendous interest being generated from our top customers. We expect the combination of the benefits from the Geneva platform and our unmatched portfolio of remote cardiac monitoring services to further solidify our leadership position in cardiac monitoring.
“BioTelemetry is in the best position ever to address the needs of our patients and practices. Looking forward, we expect the addition of Geneva and our ongoing investments in our sales and technology areas to make 2019 another record year for the Company. As a result, we are raising our full year 2019 revenue guidance to be in the range of $446 to $450 million.”
First Quarter Financial Results
Revenue for the first quarter 2019 was $104.0 million compared to $94.5 million for the first quarter 2018, an increase of $9.5 million, or 10.0%.
Gross profit for the first quarter 2019 was $64.8 million, or 62.3% of revenue, compared to $58.0 million, or 61.4% of revenue, for the first quarter 2018.
On a GAAP basis, net income attributable to BioTelemetry, Inc. for the first quarter 2019 was $11.7 million, or $0.32per diluted share, compared to net income attributable to BioTelemetry, Inc. of $6.0 million, or $0.17 per diluted share, for the first quarter 2018.
On an adjusted basis1, net income attributable to BioTelemetry, Inc. for the first quarter 2019 was $15.2 million, or $0.42 per diluted share. This compares to adjusted net income attributable to BioTelemetry, Inc. of $13.9 million, or $0.39 per diluted share, for the first quarter 2018. This increase was driven by revenue growth as well as the benefit of the synergies gained from the integration of LifeWatch. The details regarding adjusted net income are included in the reconciliation tables included in this release.
1 The Company believes that providing non-GAAP financial measures offers a meaningful representation of our performance, as we exclude expenses that are not necessary to support our ongoing business. We also make adjustments to facilitate year over year comparisons. Please refer to our “Reconciliation of GAAP to Non-GAAP Financial Measures” in this release for additional information.
BioTelemetry, Inc. will host an earnings conference call on Thursday, April 25, 2019, at 5:00 PM Eastern Time. The call will be webcast on the investor information page of our website, www.gobio.com/investors/events. The call will be archived on our website for two weeks.
BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care. We provide remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials and original equipment manufacturing that serves both healthcare and clinical research customers. More information can be found at www.gobio.com.
Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in our future. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Examples of forward-looking statements include statements we make regarding the successful execution of our operating plan, Geneva Healthcare’s actual and expected annualized revenue and profitability and the growth and success of the combined entity, our ability to increase demand for our products and services, to grow our market share and our expectations regarding revenue trends in our segments. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things: our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business; our ability to educate physicians and continue to obtain prescriptions for our products and services; changes to insurance coverage and reimbursement levels by Medicare and commercial payors for our products and services; our ability to attract and retain talented executive management and sales personnel; the commercialization of new competitive products; our ability to obtain and maintain required regulatory approvals for our products, services and manufacturing facilities; changes in governmental regulations and legislation; our ability to obtain and maintain adequate protection of our intellectual property; acceptance of our new products and services; adverse regulatory action; interruptions or delays in the telecommunications systems that we use; our ability to successfully resolve outstanding legal proceedings; and the other factors that are described in “Part I; Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2018.
We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law.
Contact: BioTelemetry, Inc.
Heather C. Getz
Executive Vice President, Chief Financial Officer
|Condensed Consolidated Statements of Operations|
|Three Months Ended
|(in thousands, except per share data)||2019||2018|
|Cost of revenues||39,201||36,448|
|Gross profit %||62.3||%||61.4||%|
|General and administrative||27,607||26,719|
|Sales and marketing||12,440||11,340|
|Bad debt expense||5,148||4,879|
|Research and development||3,333||3,289|
|Total operating expenses||51,598||51,312|
|Income from operations||13,180||6,736|
|Loss on equity method investment||(32||)||(139||)|
|Other non-operating (expense)/income, net||(1,054||)||187|
|Total other expense||(3,568||)||(1,842||)|
|Income before income taxes||9,612||4,894|
|Benefit from income taxes||2,073||142|
|Net loss attributable to noncontrolling interests||–||(946||)|
|Net income attributable to BioTelemetry, Inc.||$||11,685||$||5,982|
|Net income per share attributable to BioTelemetry, Inc.:|
|Weighted average number of common shares outstanding:|
Reconciliation of GAAP to Non-GAAP Financial Measures
|Three Months Ended|
|(Unaudited)||March 31, 2019|
|(in thousands, except per share data)||Income from
|Net income per
|Other charges (a)||3,070||3,070||3,070|
|LifeWatch amortization (b)||3,262||3,262||3,262|
|Income tax effect of adjustments (c)||–||–||(1,212||)|
|Benefit of discrete items (d)||–||–||(1,596||)|
|Three Months Ended|
|(Unaudited)||March 31, 2018|
|(in thousands, except per share data)||Income from
|Net income per
|Other charges (a)||5,085||5,085||5,085|
|LifeWatch amortization (b)||3,235||3,235||3,235|
|Income tax effect of adjustments (c)||–||–||(2,246||)|
|NOL utilization (d)||–||–||1,813|
|(Unaudited)||Three Months Ended
|Net income attributable to BioTelemetry – GAAP||$||11,685||$||5,982|
|Net loss attributable to noncontrolling interest||–||(946||)|
|Benefit from income taxes||(2,073||)||(142||)|
|Total other expense||3,568||1,842|
|Depreciation and amortization expense (a)||10,021||9,757|
|Stock compensation expense||2,549||2,065|
|Adjusted EBITDA margin||27.7||%||25.0||%|
|Ended March 31,
|Cash provided by operating activities||$||17,544||$||9,074|
|Free cash flow||$||12,210||$||5,136|
Use of Non-GAAP Financial Measures
In addition to the results prepared in accordance with generally accepted accounting principles in the United States, (“GAAP”), this press release also includes certain financial measures which have been adjusted and are not in accordance with generally accepted accounting principles (“Non-GAAP financial measures”). These Non-GAAP financial measures include adjusted income from operations, adjusted income before income taxes, adjusted net income attributable to BioTelemetry, Inc., adjusted net income per diluted share attributable to BioTelemetry, Inc., adjusted EBITDA and free cash flow. In accordance with Regulation G of the Securities and Exchange Commission, we have provided a reconciliation of these Non-GAAP financial measures with the most directly comparable financial measure calculated in accordance with GAAP.
These Non-GAAP financial measures are not intended to replace GAAP financial measures. They are presented as supplemental measures of our performance in an effort to provide our stakeholders better visibility into our ongoing operating results and to allow for comparability to prior periods as well as to other companies’ results. Management uses these Non-GAAP financial measures to assess the financial health of our ongoing operating performance. Management encourages our stakeholders to consider all of our financial measures and to not rely on any single financial measure to evaluate our performance.
Adjusted net income attributable to BioTelemetry, Inc. for the first quarter 2019 excludes other charges of $3.1 million, $3.3 million of amortization expense related to LifeWatch intangibles, the tax effect of these adjustments as well as the impact of discrete tax benefits recognized in the quarter. Adjusted net income attributable to BioTelemetry, Inc.for the first quarter 2018 excludes other charges of $5.1 million, $3.2 million of amortization expense related to LifeWatch intangibles as well as the income tax effect of these adjustments and the impact from the utilization of our net operating loss carryforwards. By excluding expenses that are considered unnecessary to support the ongoing business, are nonrecurring in nature or which limit year over year comparability, we believe these Non-GAAP financial measures offer a meaningful representation of our ongoing operating performance. Included in these excluded items are transaction related expenses, primarily legal and professional fees, integration related expenses, primarily severance, legal fees related to patent litigation, amortization of intangibles from the LifeWatch acquisition, costs related to restructuring programs aimed at streamlining operations and reducing future expense as well as other one-time items. These excluded charges are not part of the ongoing operations, and therefore, not reflective of our core operations. We view patent litigation as an extreme measure not typically required in our industry to protect a company’s intellectual property and which has not been common practice for us. We commenced patent litigation proceedings after we uncovered specific evidence of four distinct cases of misappropriation and infringement. We can choose to resolve the outstanding matters and terminate the expense at any time. We also included the income tax effect of these adjustments.
In addition to adjusted income from operations, adjusted net income attributable to BioTelemetry, Inc., adjusted net income per diluted share attributable to BioTelemetry, Inc. and free cash flow, we also present adjusted EBITDA. This Non-GAAP financial measure excludes loss from noncontrolling interest, income taxes, total other expense, other charges, depreciation and amortization and stock compensation expense. EBITDA is a widely accepted financial measure which we believe our stakeholders use to compare our ongoing financial performance to that of other companies. Adjusting our EBITDA for other charges and other one-time items is a meaningful financial measure as we believe it is an indication of our ongoing operations. In addition, we also add back stock-based compensation expense because it is non-cash in nature. Other companies in our industry may calculate adjusted EBITDA in a different manner.
Phone: 888.312.BEAT (2328)
Contact: Heather Getz, EVP, CFO&CAO